VC-backed technology company developing and delivering disruptive technologies to boost recombinant biologics production using proprietary technologies based on Baculovirus vector expression systems (BVES) in insect cells.
Supported by a first in class Scientific Advisory Board combining investment and operational experience in developing and leading companies in animal and human health.
2 proprietary and patented technology platforms, Top-Bac and CrisBio, to respond to industry’s challenges in the production of biologicals: development time, scalability, versatility and cost.
Licenses and PoCs in various protein classes and indications across Animal Health, Human Health and Diagnostics.
Learn moreHarnessing the power of insects to act as natural single-use bioreactors with chrysalises from the Trichoplusia ni Lepidopter as production tool.
Learn more
Insect rearing in disposable boxes
Pupae desilking (automated)
Clean pupae
Pupae pick & place (automated)
Baculovirus generationAutomated pupae inoculation
Frozen pupae biomass
Downstream
Purified protein
GMP
RFID-tagged disposable trays
Insect rearing in disposable boxes
Pupae desilking (automated)
Clean pupae
Pupae pick & place (automated)
RFID-tagged disposable trays
Automated pupae inoculation
Baculovirus generationGMP
Frozen pupae biomass
GMP
Downstream
GMP
Purified protein
GMP
AREAS OF FOCUS
20 years’ experience in the development and production of animal vaccines.
> 200 molecules successfully produced in collaboration with public and private partners, including multiple international pharmaceutical companies.
First dossier for a veterinary vaccine produced using CrisBio® under review by EMA.
Building on experience in animal health, Algenex is expanding the production of proteins into human health to fully exploit the potential of its technology platforms
Learn moreEVENTS & NEWS
News
Algenex inaugura su nueva planta de fabricación de vacunas e...
